ClinicalTrials.gg
TerminatedNCT02013167Updated Mar 5, 2024Results posted

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

A Phase 3 interventional study of Blinatumomab and Standard of Care Chemotherapy in Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, sponsored by Amgen. Terminated at 117 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-05.

Primary conditionPrecursor Cell Lymphoblastic Leukemia-LymphomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
405
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
8th of 61
405 · median 67
Started
2014
with 2 others
Phase 3
11 of 61
4 open now
Registered
8th of 61
by date
Lead sponsor
9 of 61
Amgen

Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 8th largest by enrollment, is one of 3 that started in 2014, is one of 11 in phase 3, and was the 8th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The primary objective was to evaluate the effect of blinatumomab on overall survival when compared to standard of care (SOC) chemotherapy.

Read the detailed description

Adults with relapsed/refractory B-cell precursor ALL were randomized in a 2:1 ratio to receive blinatumomab or 1 of 4 pre-specified, investigator-chosen, SOC chemotherapy regimens. Randomization was stratified by age (\< 35 years vs ≥ 35 years of age), prior salvage therapy (yes vs no), and prior allogeneic HSCT (yes vs no) as assessed at the time of consent.

The study consisted of up to a 3-week screening and pre-phase period, a treatment period consisting of induction with 2 cycles of either blinatumomab or SOC chemotherapy, a consolidation phase of up to 3 additional cycles of protocol-specified therapy, and a maintenance phase for up to an additional 12 months with protocol-specified therapy. A safety follow-up visit 30 days after the last dose of protocol-specified therapy and a long-term follow-up period were included. The long-term follow-up part of the study was discontinued prematurely based on a recommendation from the data monitoring committee (DMC) that the study be stopped for benefit.

03

Conditions studied

  • Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Browse trials for

Keywords

  • Relapsed; Refractory; B-precursor; Acute Lymphoblastic Leukemia; Philadelphia Negative; ALL; Blinatumomab; Leukemia; Standard of Care; SOC
04

In context

Precursor Cell Lymphoblastic Leukemia-Lymphoma Reclassified

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.

This study's enrollment of 405 is above the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Precursor Cell Lymphoblastic Leukemia-Lymphoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Subjects with Philadelphia negative B-precursor ALL, with any of the following:

    • to primary induction therapy or refractory to salvage therapy,
    • in untreated first relapse with first remission duration \<12 months
    • in untreated second or greater relapse
    • relapse at any time after HSCT
  • Subject has received intensive combination chemotherapy for the treatment of ALL for initial treatment or subsequent salvage therapy.
  • Greater than 5% blasts in the bone marrow
  • (ECOG) performance status ≤ 2

Exclusion Criteria

  • other than ALL within 5 years before blinatumomab treatment, except for adequately treated selected cancers without evidence of disease
  • Diagnosis of Burkitt's leukemia according to World Health Organization classification, or (HIV), or C, or other disorder
  • Current relevant central nervous system (CNS) pathology or known or suspected CNS involvement
  • Isolated extramedullary disease
  • Current disease or history of autoimmune disease with potential CNS involvement
  • Autologous HSCT within 6 weeks or allogeneic HSCT within 12 weeks before blinatumomab treatment, or eligibility for allogeneic HSCT at the time of enrollment
  • Active acute grade 2 to 4 (GvHD) according to Glucksberg et al (1974) criteria that required systemic treatment to prevent or treat GvHD 2 weeks before blinatumomab treatment
  • Known exclusion criteria to investigator choice of SOC chemotherapy (per package insert)
  • Cancer chemotherapy or radiotherapy with 2 weeks, or immunotherapy (included CD19 therapy) within 4 weeks of protocol-specified therapy
  • Abnormal laboratory values (alanine or [ALT or AST] or alkaline phosphatase [ALP] ≥ 5 × [ULN]; total or creatinine ≥ 1.5 × ULN), or calculated \< 60 mL/min.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    Blinatumomab

    Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh\*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab. Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh\*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period. The initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles.

    Drug: Blinatumomab

  • Active comparator
    Standard of Care Chemotherapy

    Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh\*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy. Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh\*/CRi could continue to receive SOC therapy for an additional 12 months.

    Drug: Standard of Care Chemotherapy

Interventions

  • Blinatumomab is administered as a continuous intravenous infusion (CIV).

    Also known as: Blincyto®, AMG 103, MT103

  • DrugStandard of Care Chemotherapy

    * FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 \& 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients \> 60 years: Idarubicin 5 mg/m² day 1 \& 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5 * HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents * High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents. * Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days.

07

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival (OS) was calculated from time of randomization until death due to any cause. Participants still alive were censored at the date they were last known to be alive.

    Time frame: From randomization until the data cut-off date of 04 January 2016; median observation time was 11.8 months in the SOC group and 11.7 months in the blinatumomab group.

Secondary outcomes

  1. Percentage of Participants With Complete Remission Within 12 Weeks of Treatment Initiation

    Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts. Complete Remission (CR) was defined as having ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/μl, and absolute neutrophil count (ANC) \> 1,000/μl. CR must have occurred within 12 weeks of the first dose of therapy.

    Time frame: 12 weeks

  2. Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi) Within 12 Weeks of Treatment Initiation

    Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts. Complete remission was defined as having ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/μl, and ANC \> 1,000/μl. Complete Remission with partial hematological recovery (CRh\*) was defined as ≤ 5% blasts in the bone marrow, no evidence of disease and partial recovery of peripheral blood counts: platelets \> 50,000/μl, and ANC \> 500/μl. Complete remission with incomplete hematological recovery (CRi) was defined as ≤ 5% blasts in the bone marrow, no evidence of disease and incomplete recovery of peripheral blood counts: platelets \> 100,000/μl or ANC \> 1000 (but not both).

    Time frame: 12 weeks

  3. Event Free Survival (EFS)

    Event free survival was defined as the time from randomization until a documented relapse after achieving CR/CRh\*/CRi or death, whichever occurred first. Participants who failed to achieve a CR/CRh\*/CRi within 12 weeks of treatment initiation were considered as non-responders and assigned an EFS duration of 1 day. Participants still alive and relapse-free were censored on their last disease assessment date. A relapse event was any one of the following: * Hematological relapse: proportion of blasts in bone marrow \>5% or blasts in peripheral blood after documented CR or CRh\* or CRi * Progressive disease: An increase from baseline of at least 25% of bone marrow blasts or an absolute increase of at least 5,000 cells/μL in the number of circulating leukemia cells * Extramedullary relapse: extramedullary lesion that is new or increased by 50% from nadir as assessed by Cheson criteria. The Kaplan-Meier estimate of EFS at 6 months is reported.

    Time frame: 6 months

  4. Duration of Complete Remission

    Duration of complete remission, calculated only for participants who achieved a CR, was calculated from the date a CR was first achieved until the earliest date of a disease assessment indicating a relapse event or death, whichever occurred first. Participants who did not have a relapse event were censored on their last disease assessment date.

    Time frame: Up to the data cut-off date of 04 January 2016; median observation time was 10.8 months in the SOC group and 7.0 months in the blinatumomab group.

  5. Duration of Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi)

    Duration of CR/CRh\*/CRi, calculated only for participants who achieved a CR/CRh\*/CRi, was calculated from the date a CR/CRh\*/CRi was first achieved until the earliest date of a disease assessment indicating a relapse event or death, whichever occurred first. Participants who did not have a relapse event were censored on their last disease assessment date.

    Time frame: Up to the data cut-off date of 04 January 2016; median observation time was 10.8 months in the SOC group and 7.2 months in the blinatumomab group.

  6. Percentage of Participants With Minimal Residual Disease (MRD) Within 12 Weeks of Treatment Initiation

    Bone marrow samples were evaluated for MRD remission by a central laboratory. MRD remission was defined as the occurrence of an MRD level below 10\^-4 measured by quantitative reverse transcription polymerase chain reaction (PCR) or flow cytometry.

    Time frame: 12 weeks

  7. Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

    Time frame: Up to the data cut-off date of 04 January 2016; maximum time on study was 23 months.

  8. Number of Participants With Adverse Events

    Adverse events (AEs) were graded for severity according to the CTCAE version 4.0, where Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE. Treatment-related adverse events (TRAEs) were those assessed by the investigator as possibly related to blinatumomab based on response to the question: Is there a reasonable possibility that the event may have been caused by blinatumomab or other protocol-specified therapies/procedures?

    Time frame: From first dose of protocol-specified therapy until 30 days after the last dose, up to the data cut-off date of 04 January 2016; median duration of treatment was 5 days in the SOC group and 70 days in the blinatumomab group.

  9. 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant

    The analysis of 100-day mortality after allogeneic HSCT was assessed for participants who achieved a best response of CR/CRh\*CTi within 12 weeks of treatment initiation, who received an allogeneic HSCT and did not receive any additional anticancer treatment before the transplant. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT. The 100-day mortality rate after allogeneic HSCT was defined as the percentage of participants having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive.

    Time frame: 100 days, from the date of allogeneic HSCT until the data cut-off date of 04 January 2016

  10. Number of Participants With Anti-blinatumomab Antibodies

    Anti-blinatumomab binding antibodies were evaluated using a validated electrochemiluminescence (ECL)-based assay (binding assay). Samples positive for binding were analyzed using a cell-based bioassay to determine if the detected antibodies had neutralizing properties (neutralizing assay).

    Time frame: Samples were collected on day 29 at the end of cycle 2 and 30 days after the last dose of blinatumomab (median duration of treatment was 70 days).

  11. Time to a 10-point Decrease From Baseline in Global Health Status and Quality of Life or Death

    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is a 30-item questionnaire that assesses the health related quality of life of cancer patients. The EORTC QLQ-C30 consists of a global health status/quality of life (QoL) scale, 5 functional scales, 3 symptom scales, and 6 single items. The global health/QoL scale consists of 2 questions that ask participants to rate their overall health and overall quality of life durig the past week on a scale from 1 (very poor) to 7 (excellent). The scale score was derived as the sum of each score and transformed to a scale from 0 to 100 where higher scores represent a high QoL. Time to a ≥10-point decrease from baseline GHS/QoL or death, whichever came first, was calculated from baseline. Participants still alive and without a 10-point decrease in GHS/QoL EORTC QLQ-C30 were censored on their last EORTC QLQ-C30 assessment date.

    Time frame: From randomization until the data cut-off date of 04 January 2016; EORTC QLQ-C30 was assessed on day 1, 8, 15, and 29 during cycle 1; days 1, 15, and 29 in cycle 2 and each consolidation cycle, and 30-days following the last dose of drug treatment.

08

Results

Posted Aug 9, 2017

Participant flow

This study was conducted at 101 centers in 21 countries in Asia, Australia, Europe, and Latin and North America. The first participant was enrolled on 03 January 2014 and treated on 06 January 2014. The last participant enrolled on 25 September 2015 and the data cutoff date for this report was 04 January 2016.

Participant flow — Overall Study
MilestoneStandard of Care ChemotherapyBlinatumomab
Started134271
Received treatment109267
Completed3393
Not completed101178
Withdrew: Withdrawal by subject1514
Withdrew: Sponsor decision13
Withdrew: Lost to follow-up01
Withdrew: Death85160

Outcome measures

PrimaryOverall Survival

Overall survival (OS) was calculated from time of randomization until death due to any cause. Participants still alive were censored at the date they were last known to be alive.

Time frame:
From randomization until the data cut-off date of 04 January 2016; median observation time was 11.8 months in the SOC group and 11.7 months in the blinatumomab group.
Reported as:
Median · months
Overall Survival
monthsStandard of Care ChemotherapyBlinatumomab
Overall Survival4.0 (2.9 to 5.3)7.7 (5.6 to 9.6)
Statistical analysis
  • Standard of Care Chemotherapy vs Blinatumomab · Stratified Log Rank · p = 0.012 · Hazard ratio (hr): 0.71 · 95% CI 0.55 to 0.93Hazard ratio obtained from the Cox Proportional Hazard Model. A hazard ratio \< 1.0 indicated a lower average event rate and longer survival time for blinatumomab relative to SOC chemotherapy.
SecondaryPercentage of Participants With Complete Remission Within 12 Weeks of Treatment Initiation

Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts. Complete Remission (CR) was defined as having ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/μl, and absolute neutrophil count (ANC) \> 1,000/μl. CR must have occurred within 12 weeks of the first dose of therapy.

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission Within 12 Weeks of Treatment Initiation
percentage of participantsStandard of Care ChemotherapyBlinatumomab
Percentage of Participants With Complete Remission Within 12 Weeks of Treatment Initiation15.7 (10.0 to 23.0)33.6 (28.0 to 39.5)
Statistical analysis
  • Standard of Care Chemotherapy vs Blinatumomab · Cochran-Mantel-Haenszel · p = < 0.001 · Treatment difference: 17.9 · 95% CI 9.6 to 26.2Adjusted for the stratification factors: age (\< 35 vs. ≥ 35), prior salvage therapy (yes vs. no), and prior allogeneic HSCT (yes vs. no).
SecondaryPercentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi) Within 12 Weeks of Treatment Initiation

Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts. Complete remission was defined as having ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/μl, and ANC \> 1,000/μl. Complete Remission with partial hematological recovery (CRh\*) was defined as ≤ 5% blasts in the bone marrow, no evidence of disease and partial recovery of peripheral blood counts: platelets \> 50,000/μl, and ANC \> 500/μl. Complete remission with incomplete hematological recovery (CRi) was defined as ≤ 5% blasts in the bone marrow, no evidence of disease and incomplete recovery of peripheral blood counts: platelets \> 100,000/μl or ANC \> 1000 (but not both).

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi) Within 12 Weeks of Treatment Initiation
percentage of participantsStandard of Care ChemotherapyBlinatumomab
Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi) Within 12 Weeks of Treatment Initiation24.6 (17.6 to 32.8)43.9 (37.9 to 50.0)
Statistical analysis
  • Standard of Care Chemotherapy vs Blinatumomab · Cochran-Mantel-Haenszel · p = < 0.001 · Treatment difference: 19.3 · 95% CI 9.9 to 28.7Adjusted for the stratification factors: age (\< 35 vs. ≥ 35), prior salvage therapy (yes vs. no), and prior allogeneic HSCT (yes vs. no).
SecondaryEvent Free Survival (EFS)

Event free survival was defined as the time from randomization until a documented relapse after achieving CR/CRh\*/CRi or death, whichever occurred first. Participants who failed to achieve a CR/CRh\*/CRi within 12 weeks of treatment initiation were considered as non-responders and assigned an EFS duration of 1 day. Participants still alive and relapse-free were censored on their last disease assessment date. A relapse event was any one of the following: * Hematological relapse: proportion of blasts in bone marrow \>5% or blasts in peripheral blood after documented CR or CRh\* or CRi * Progressive disease: An increase from baseline of at least 25% of bone marrow blasts or an absolute increase of at least 5,000 cells/μL in the number of circulating leukemia cells * Extramedullary relapse: extramedullary lesion that is new or increased by 50% from nadir as assessed by Cheson criteria. The Kaplan-Meier estimate of EFS at 6 months is reported.

Time frame:
6 months
Reported as:
Number · percentage of participants
Event Free Survival (EFS)
percentage of participantsStandard of Care ChemotherapyBlinatumomab
Event Free Survival (EFS)12.5 (7.2 to 19.2)30.7 (25.0 to 36.5)
Statistical analysis
  • Standard of Care Chemotherapy vs Blinatumomab · Hazard ratio (hr): 0.55 · 95% CI 0.43 to 0.71The hazard ratio estimates were obtained from the Cox Proportional Hazard Model. A hazard ratio \< 1.0 indicates a lower average event rate and a longer survival for Blinatumomab relative to SOC Chemotherapy.
SecondaryDuration of Complete Remission

Duration of complete remission, calculated only for participants who achieved a CR, was calculated from the date a CR was first achieved until the earliest date of a disease assessment indicating a relapse event or death, whichever occurred first. Participants who did not have a relapse event were censored on their last disease assessment date.

Time frame:
Up to the data cut-off date of 04 January 2016; median observation time was 10.8 months in the SOC group and 7.0 months in the blinatumomab group.
Reported as:
Median · months
Duration of Complete Remission
monthsStandard of Care ChemotherapyBlinatumomab
Duration of Complete Remission7.8 (2.2 to 19.0)8.3 (5.7 to 10.7)
SecondaryDuration of Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi)

Duration of CR/CRh\*/CRi, calculated only for participants who achieved a CR/CRh\*/CRi, was calculated from the date a CR/CRh\*/CRi was first achieved until the earliest date of a disease assessment indicating a relapse event or death, whichever occurred first. Participants who did not have a relapse event were censored on their last disease assessment date.

Time frame:
Up to the data cut-off date of 04 January 2016; median observation time was 10.8 months in the SOC group and 7.2 months in the blinatumomab group.
Reported as:
Median · months
Duration of Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi)
monthsStandard of Care ChemotherapyBlinatumomab
Duration of Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi)4.6 (1.8 to 19.0)7.3 (5.8 to 9.9)
SecondaryPercentage of Participants With Minimal Residual Disease (MRD) Within 12 Weeks of Treatment Initiation

Bone marrow samples were evaluated for MRD remission by a central laboratory. MRD remission was defined as the occurrence of an MRD level below 10\^-4 measured by quantitative reverse transcription polymerase chain reaction (PCR) or flow cytometry.

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Minimal Residual Disease (MRD) Within 12 Weeks of Treatment Initiation
percentage of participantsStandard of Care ChemotherapyBlinatumomab
Percentage of Participants With Minimal Residual Disease (MRD) Within 12 Weeks of Treatment Initiation14.2 (8.8 to 21.3)29.9 (24.5 to 35.7)
SecondaryPercentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Time frame:
Up to the data cut-off date of 04 January 2016; maximum time on study was 23 months.
Reported as:
Number · percentage of participants
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
percentage of participantsStandard of Care ChemotherapyBlinatumomab
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)23.9 (16.9 to 32.0)24.0 (19.0 to 29.5)
SecondaryNumber of Participants With Adverse Events

Adverse events (AEs) were graded for severity according to the CTCAE version 4.0, where Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE. Treatment-related adverse events (TRAEs) were those assessed by the investigator as possibly related to blinatumomab based on response to the question: Is there a reasonable possibility that the event may have been caused by blinatumomab or other protocol-specified therapies/procedures?

Time frame:
From first dose of protocol-specified therapy until 30 days after the last dose, up to the data cut-off date of 04 January 2016; median duration of treatment was 5 days in the SOC group and 70 days in the blinatumomab group.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsStandard of Care ChemotherapyBlinatumomab
Any adverse event108263
AE grade ≥ 2106256
AE grade ≥ 3100231
AE grade ≥ 467133
Serious adverse events49165
AEs leading to interruption of study drug686
AEs leading to discontinuation of study drug933
Life-threatening adverse events2655
Fatal adverse events1951
Treatment-related adverse events92214
Treatment-related AE grade ≥ 289195
Treatment-related AE grade ≥ 378143
Treatment-related AE grade ≥ 45157
Serious treatment-related adverse events3474
TRAEs leading to interruption of study drug658
TRAEs leading to discontinuation of study drug819
Treatment-related life-threatening adverse events1721
Treatment-related fatal adverse events88
Secondary100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant

The analysis of 100-day mortality after allogeneic HSCT was assessed for participants who achieved a best response of CR/CRh\*CTi within 12 weeks of treatment initiation, who received an allogeneic HSCT and did not receive any additional anticancer treatment before the transplant. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT. The 100-day mortality rate after allogeneic HSCT was defined as the percentage of participants having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive.

Time frame:
100 days, from the date of allogeneic HSCT until the data cut-off date of 04 January 2016
Reported as:
Number · percentage of participants
100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant
percentage of participantsStandard of Care ChemotherapyBlinatumomab
100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant0.0 (NA to NA)12.4 (4.8 to 29.9)
SecondaryNumber of Participants With Anti-blinatumomab Antibodies

Anti-blinatumomab binding antibodies were evaluated using a validated electrochemiluminescence (ECL)-based assay (binding assay). Samples positive for binding were analyzed using a cell-based bioassay to determine if the detected antibodies had neutralizing properties (neutralizing assay).

Time frame:
Samples were collected on day 29 at the end of cycle 2 and 30 days after the last dose of blinatumomab (median duration of treatment was 70 days).
Reported as:
Number · participants
Number of Participants With Anti-blinatumomab Antibodies
participantsBlinatumomab
Binding antibody positive5
Neutralizing antibody positive3
SecondaryTime to a 10-point Decrease From Baseline in Global Health Status and Quality of Life or Death

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is a 30-item questionnaire that assesses the health related quality of life of cancer patients. The EORTC QLQ-C30 consists of a global health status/quality of life (QoL) scale, 5 functional scales, 3 symptom scales, and 6 single items. The global health/QoL scale consists of 2 questions that ask participants to rate their overall health and overall quality of life durig the past week on a scale from 1 (very poor) to 7 (excellent). The scale score was derived as the sum of each score and transformed to a scale from 0 to 100 where higher scores represent a high QoL. Time to a ≥10-point decrease from baseline GHS/QoL or death, whichever came first, was calculated from baseline. Participants still alive and without a 10-point decrease in GHS/QoL EORTC QLQ-C30 were censored on their last EORTC QLQ-C30 assessment date.

Time frame:
From randomization until the data cut-off date of 04 January 2016; EORTC QLQ-C30 was assessed on day 1, 8, 15, and 29 during cycle 1; days 1, 15, and 29 in cycle 2 and each consolidation cycle, and 30-days following the last dose of drug treatment.
Reported as:
Median · months
Time to a 10-point Decrease From Baseline in Global Health Status and Quality of Life or Death
monthsStandard of Care ChemotherapyBlinatumomab
Time to a 10-point Decrease From Baseline in Global Health Status and Quality of Life or Death1.0 (0.5 to 1.5)1.7 (1.1 to 3.6)

Adverse events

Collected over From first dose of protocol-specified therapy until 30 days after the last dose, up to the data cut-off date of 04 January 2016; median duration of treatment was 5 days in the SOC group and 70 days in the blinatumomab group.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care Chemotherapy—49/109 (45%)105/109 (96.3%)
Blinatumomab—165/267 (61.8%)250/267 (93.6%)
Most frequent serious events
Showing 10 of 187
Most frequent serious events
EventStandard of Care ChemotherapyBlinatumomab
Febrile neutropeniaBlood and lymphatic system disorders12/10923/267
SepsisInfections and infestations7/10913/267
PyrexiaGeneral disorders1/10916/267
PneumoniaInfections and infestations2/10910/267
Septic shockInfections and infestations3/1098/267
OverdoseInjury, poisoning and procedural complications0/1098/267
BacteraemiaInfections and infestations3/1092/267
Cytokine release syndromeImmune system disorders0/1097/267
Bacterial sepsisInfections and infestations2/1096/267
Device related infectionInfections and infestations1/1096/267
Most frequent other events
Showing 10 of 62
Most frequent other events
EventStandard of Care ChemotherapyBlinatumomab
PyrexiaGeneral disorders48/109153/267
AnaemiaBlood and lymphatic system disorders46/10969/267
NauseaGastrointestinal disorders46/10951/267
DiarrhoeaGastrointestinal disorders38/10958/267
Febrile neutropeniaBlood and lymphatic system disorders36/10948/267
ThrombocytopeniaBlood and lymphatic system disorders32/10947/267
HeadacheNervous system disorders32/10977/267
NeutropeniaBlood and lymphatic system disorders31/10951/267
HypokalaemiaMetabolism and nutrition disorders30/10945/267
ConstipationGastrointestinal disorders28/10934/267

Baseline characteristics

Age, Continuous
Age, Continuous(years)Standard of Care ChemotherapyBlinatumomabTotal
Mean41.1 ± 17.340.8 ± 17.140.9 ± 17.2
Age, Customized
Age, Customized(participants)Standard of Care ChemotherapyBlinatumomabTotal
< 35 years60124184
35 to 54 years3380113
55 to 64 years263460
≥ 65 years153348
Sex: Female, Male
Sex: Female, Male(Participants)Standard of Care ChemotherapyBlinatumomabTotal
Female57109166
Male77162239
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Standard of Care ChemotherapyBlinatumomabTotal
Hispanic or Latino112637
Not Hispanic or Latino122243365
Unknown or Not Reported123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Standard of Care ChemotherapyBlinatumomabTotal
American Indian or Alaska Native145
Asian91928
Native Hawaiian or Other Pacific Islander112
Black or African American358
White112228340
Multiple022
Other81220
Age Stratification at Randomization
Age Stratification at Randomization(participants)Standard of Care ChemotherapyBlinatumomabTotal
< 35 years60123183
≥ 35 years74148222
Prior Salvage Therapy Stratification at Randomization
Prior Salvage Therapy Stratification at Randomization(participants)Standard of Care ChemotherapyBlinatumomabTotal
Yes80164244
No54107161
Prior Allogeneic Hematopoietic Stem Cell Transplant (HCST)
Prior Allogeneic Hematopoietic Stem Cell Transplant (HCST)(participants)Standard of Care ChemotherapyBlinatumomabTotal
Yes4694140
No88177265

1 further baseline measures are reported on the registry.

09

Study locations

117 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Boston, Massachusetts 02111, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Greenville, South Carolina 29607, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    St Leonards, New South Wales 2065, Australia
  • Research Site
    Herston, Queensland 4029, Australia
  • Research Site
    Adelaide, South Australia 5000, Australia
  • Research Site
    Parkville, Victoria 3050, Australia
  • Research Site
    Prahran, Victoria 3181, Australia
  • Research Site
    Murdoch, Western Australia 6150, Australia
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Wels, 4600, Austria
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Wien, 1140, Austria
  • Research Site
    Antwerpen, 2060, Belgium
  • Research Site
    Brugge, 8000, Belgium
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Yvoir, 5530, Belgium
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Sofia, 1756, Bulgaria
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Praha 10, 100 34, Czechia
  • Research Site
    Praha 2, 128 20, Czechia
  • Research Site
    Creteil Cedex, 94010, France
  • Research Site
    Le Chesnay, 78157, France
  • Research Site
    Nantes Cedex 1, 44093, France
  • Research Site
    Paris Cedex 10, 75475, France
  • Research Site
    Pessac Cedex, 33604, France
  • Research Site
    Pierre-Benite, 69495, France
  • Research Site
    Toulouse cedex 9, 31059, France
  • Research Site
    Berlin, 12200, Germany
  • Research Site
    Essen, 45147, Germany
  • Research Site
    Frankfurt am Main, 60590, Germany
  • Research Site
    Freiburg, 79106, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Kiel, 24116, Germany
  • Research Site
    Köln, 50937, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Würzburg, 97080, Germany
  • Research Site
    Athens, 10676, Greece
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Ioannina, 45110, Greece
  • Research Site
    Patra, 26500, Greece
  • Research Site
    Thessaloniki, 57010, Greece
  • Research Site
    Dublin, 8, Ireland
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Jerusalem, 91031, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Petah Tikva, 49100, Israel
  • Research Site
    Tel Aviv, 64239, Israel
  • Research Site
    Tel Hashomer, 52621, Israel
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Bergamo, 24127, Italy
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Firenze, 50134, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Novara, 28100, Italy
  • Research Site
    Palermo, 90146, Italy
  • Research Site
    Roma, 00133, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Venezia, 30174, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Busan, 614-735, Korea, Republic of
  • Research Site
    Seoul, 110-744, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Seoul, 138-736, Korea, Republic of
  • Research Site
    Mexico City, Distrito Federal 07760, Mexico
  • Research Site
    Monterrey, Nuevo León 64460, Mexico
  • Research Site
    Lublin, 20-081, Poland
  • Research Site
    Warszawa, 02-776, Poland
  • Research Site
    Warszawa, 04-141, Poland
  • Research Site
    Wroclaw, 50-367, Poland
  • Research Site
    Moscow, 125167, Russian Federation
  • Research Site
    Nizhny Novgorod, 603126, Russian Federation
  • Research Site
    Petrozavodsk, 185019, Russian Federation
  • Research Site
    Saratov, 410012, Russian Federation
  • Research Site
    Oviedo, Asturias 33011, Spain
  • Research Site
    Salamanca, Castilla León 37007, Spain

Showing the first 100 of 117 sites across 21 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Delea TE, Amdahl J, Boyko D, Hagiwara M, Zimmerman ZF, Franklin JL, Cong Z, Hechmati G, Stein A. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. J Med Econ. 2017 Sep;20(9):911-922. doi: 10.1080/13696998.2017.1344127. Epub 2017 Jul 11. PubMed 28631497 ↗
  • Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foa R, Bassan R, Arslan O, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Bruggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783. PubMed 28249141 ↗
  • Dombret H, Topp MS, Schuh AC, Wei AH, Durrant S, Bacon CL, Tran Q, Zimmerman Z, Kantarjian H. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019 Sep;60(9):2214-2222. doi: 10.1080/10428194.2019.1576872. Epub 2019 Apr 5. PubMed 30947585 ↗
  • Kuchimanchi M, Zhu M, Clements JD, Doshi S. Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy. Br J Clin Pharmacol. 2019 Apr;85(4):807-817. doi: 10.1111/bcp.13864. Epub 2019 Feb 18. PubMed 30645768 ↗
  • Stein AS, Larson RA, Schuh AC, Stevenson W, Lech-Maranda E, Tran Q, Zimmerman Z, Kormany W, Topp MS. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv. 2018 Jul 10;2(13):1522-1531. doi: 10.1182/bloodadvances.2018019034. PubMed 29954814 ↗
  • Topp MS, Zimmerman Z, Cannell P, Dombret H, Maertens J, Stein A, Franklin J, Tran Q, Cong Z, Schuh AC. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood. 2018 Jun 28;131(26):2906-2914. doi: 10.1182/blood-2017-09-804658. Epub 2018 May 8. PubMed 29739753 ↗
  • Kantarjian HM, Zugmaier G, Bruggemann M, Wood BL, Horst HA, Zeng Y, Martinelli G. Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Cancers (Basel). 2021 Nov 9;13(22):5607. doi: 10.3390/cancers13225607. PubMed 34830762 ↗
  • Horst HA, Zugmaier G, Martinelli G, Mergen N, Velasco K, Zaman F, Kantarjian H. CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis. Am J Hematol. 2023 Aug;98(8):E222-E225. doi: 10.1002/ajh.26988. Epub 2023 Jun 22. No abstract available. PubMed 37345570 ↗
  • Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704. PubMed 35622074 ↗
  • Jabbour E, Patel K, Jain N, Duose D, Luthra R, Short NJ, Zugmaier G, San Lucas A, Velasco K, Tran Q, Zaman F, Konopleva M, Kantarjian H. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. Am J Hematol. 2021 Oct 1;96(10):E379-E383. doi: 10.1002/ajh.26281. Epub 2021 Jul 7. No abstract available. PubMed 34161631 ↗
  • Wei AH, Ribera JM, Larson RA, Ritchie D, Ghobadi A, Chen Y, Anderson A, Dos Santos CE, Franklin J, Kantarjian H. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021 Aug;35(8):2220-2231. doi: 10.1038/s41375-020-01089-x. Epub 2021 Feb 4. PubMed 33542479 ↗
  • Rambaldi A, Huguet F, Zak P, Cannell P, Tran Q, Franklin J, Topp MS. Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia. Blood Adv. 2020 Apr 14;4(7):1518-1525. doi: 10.1182/bloodadvances.2019000874. PubMed 32289160 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in Dec 2015, 23 months.

Results were first posted in Aug 2017, 1 year 7 months after primary completion. A results delay was requested in Oct 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2013
First posted
Dec 17, 2013
StartActual
Jan 3, 2014
Primary completionActual
Dec 29, 2015
CompletionActual
Mar 14, 2017
Results delay requested
Oct 14, 2016
Results first posted
Aug 9, 2017
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02013167
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 17, 2013
Start date
Jan 3, 2014
Primary completion
Dec 29, 2015
Completion
Mar 14, 2017
Results posted
Aug 9, 2017
Last update
Mar 5, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion